Latest advances of glucagon-like peptide-1 on polycystic ovary syndrome / 中国医师杂志

Polycystic ovary syndrome (PCOS) is a common endocrine metabolic disorder of reproductive age women,often accompanied by obesity,hyperandrogenism,hyperinsulinemia,insulin resistance (IR),and other metabolic syndrome (MS).Oxidative stress (OS) is considered as a potential inducing factor in the pathogenesis of PCOS at present.Glucagon-like peptide-1 (glp-1) receptor agonist and analogues as new therapeutic agents in the treatment of type 2 diabetes mellitus (T2DM),can lose weight,improve IR,resist OS and reduce the expression of inflammatory cytokines,thus they have been widely used in the clinical application of patients with PCOS.The author reviews the latest advances of glucagon-like peptide-1 on polycystic ovary syndrome.